Immune response following infection with SARS‐CoV ‐2 and other coronaviruses: A rapid review
Tóm tắt
In this review, we systematically searched and summarized the evidence on the immune response and reinfection rate following SARS‐CoV‐2 infection. We also retrieved studies on SARS‐CoV and MERS‐CoV to assess the long‐term duration of antibody responses. A protocol based on Cochrane rapid review methodology was adhered to and databases were searched from 1/1/2000 until 26/5/2020.
Of 4744 citations retrieved, 102 studies met our inclusion criteria. Seventy‐four studies were retrieved on SARS‐CoV‐2. While the rate and timing of IgM and IgG seroconversion were inconsistent across studies, most seroconverted for IgG within 2 weeks and 100% (N = 62) within 4 weeks. IgG was still detected at the end of follow‐up (49‐65 days) in all patients (N = 24). Neutralizing antibodies were detected in 92%‐100% of patients (up to 53 days). It is not clear if reinfection with SARS‐CoV‐2 is possible, with studies more suggestive of intermittent detection of residual RNA.
Twenty‐five studies were retrieved on SARS‐CoV. In general, SARS‐CoV‐specific IgG was maintained for 1‐2 years post‐infection and declined thereafter, although one study detected IgG up to 12 years post‐infection. Neutralizing antibodies were detected up to 17 years in another study. Three studies on MERS‐CoV reported that IgG may be detected up to 2 years.
In conclusion, limited early data suggest that most patients seroconvert for SARS‐CoV‐2‐specific IgG within 2 weeks. While the long‐term duration of antibody responses is unknown, evidence from SARS‐CoV studies suggest SARS‐CoV‐specific IgG is sustained for 1‐2 years and declines thereafter.
Từ khóa
Tài liệu tham khảo
HIQA. Health Information and Quality Authority. Protocol for evidence synthesis support ‐ COVID‐19.https://www.hiqa.ie/sites/default/files/2020‐05/Protocol‐for‐HIQA‐COVID‐19‐evidence‐synthesis‐support_1‐6.pdf.2020. Accessed June 1 2020.
GarrittyC GartlehnerG KamelCet al.Cochrane Rapid Reviews. Interim Guidance from the Cochrane Rapid Reviews Methods Group; March2020.
WellsGA SheaB O'ConnellD et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed August 14 2020.
AdamsER AnandR AnderssonMI et al. Evaluation of antibody testing for SARS‐Cov‐2 using ELISA and lateral flow immunoassays.medRxiv. 2020. doi:https://doi.org/10.1101/2020.04.15.20066407.
AnJ LiaoX XiaoT et al. Clinical characteristics of the recovered COVID‐19 patients with re‐detectable positive RNA test.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.26.20044222.
Baettig SJ, 2020, Case series of coronavirus (SARS‐CoV‐2) in a military recruit school: clinical, sanitary and logistical implications, BMJ Mil Health, 1
Brandstetter S, 2020, Symptoms and immunoglobulin development in hospital staff exposed to a SARS‐CoV‐2 outbreak, Pediatr Allergy Immunol, 1
DahlkeC HeidepriemJ KobbeR et al. Distinct early IgA profile may determine severity of COVID‐19 symptoms: an immunological case series.medRxiv. 2020. doi:https://doi.org/10.1101/2020.04.14.20059733.
DongC NiL YeF et al. Characterization of anti‐viral immunity in recovered individuals infected by SARS‐CoV‐2.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.17.20036640.
Fan BX, 2005, Study on the dynamics of IgG antibody in 311 patients with severe acute respiratory syndrome, Zhonghua Liu Xing Bing Xue Za Zhi, 26, 194
FuS FuX SongY et al. Virologic and clinical characteristics for prognosis of severe COVID‐19: a retrospective observational study in Wuhan China.medRxiv. 2020. doi:https://doi.org/10.1101/2020.04.03.20051763.
GrzelakL TemmamS PlanchaisC et al. SARS‐CoV‐2 serological analysis of COVID‐19 hospitalized patients pauci‐symptomatic individuals and blood donors.medRxiv. 2020. doi:https://doi.org/10.1101/2020.04.21.20068858.
GuoX GuoZ DuanC et al. Long‐term persistence of IgG antibodies in SARS‐CoV infected healthcare workers.medRxiv. 2020. doi:https://doi.org/10.1101/2020.02.12.20021386.
HuQ CuiX LiuX et al. The production of antibodies for SARS‐CoV‐2 and its clinical implication. medRxiv; 2020. doi:https://doi.org/10.1101/2020.04.20.20065953.
HuangJ MaoT LiS et al. Long period dynamics of viral load and antibodies for SARS‐CoV‐2 infection: an observational cohort study.medRxiv. 2020. doi:https://doi.org/10.1101/2020.04.22.20071258.
HuangJ ZhengL LiZ et al. Recurrence of SARS‐CoV‐2 PCR positivity in COVID‐19 patients: a single center experience and potential implications.medRxiv. 2020. doi:https://doi.org/10.1101/2020.05.06.20089573.
JiaX ZhangP TianY et al. Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID‐19 infection.medRxiv. 2020. doi:https://doi.org/10.1101/2020.02.28.20029025.
JiangH‐W LiY ZhangH‐N et al. Global profiling of SARS‐CoV‐2 specific IgG/IgM responses of convalescents using a proteome microarray.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.20.20039495.
Li Y, 2004, Protective effect of specific antibody in serum of convalescent patient with SARS, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 16, 409
LiuL LiuW WangS ZhengS.A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in 238 admitted hospital patients.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.06.20031856.
LiuR LiuX HanH et al. The comparative superiority of IgM‐IgG antibody test to real‐time reverse transcriptase PCR detection for SARS‐CoV‐2 infection diagnosis.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.28.20045765.
PhippsW SoRelleJ LiQ‐Z et al. SARS‐CoV‐2 antibody responses do not predict COVID‐19 disease severity.medRxiv. 2020. doi:https://doi.org/10.1093/ajcp/aqaa123.
Wang J‐C, 2020, Recurrence of Positive SARS‐CoV‐2 Viral RNA in Recovered COVID‐19 Patients during Medical Isolation Observation
Wang X, 2020, Neutralizing antibodies responses to SARS‐CoV‐2 in COVID‐19 inpatients and convalescent patients, Clin Infect Dis, ciaa721
Xie J, 2006, Dynamic changes of T lymphocyte subsets in the long‐term follow‐up of severe acute respiratory syndrome patients, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 28, 253
ZhangN GongY MengF BiY YangP WangF. Virus shedding patterns in nasopharyngeal and fecal specimens of COVID‐19 patients.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.28.20043059.
TanW LuY ZhangJ et al. Viral kinetics and antibody responses in patients with COVID‐19.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.24.20042382.
Wang Y, 2020, A Case Report of Moderate COVID‐19 with an Extremely Long‐Term Viral Shedding Period in China
Zhao J, 2020, Early virus clearance and delayed antibody response in a case of COVID‐19 with a history of co‐infection with HIV‐1 and HCV, Clin Infect Dis
LongQ‐x DengH‐j ChenJ et al. Antibody responses to SARS‐CoV‐2 in COVID‐19 patients: the perspective application of serological tests in clinical practice.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.18.20038018.
LouB LiT ZhengS et al. Serology characteristics of SARS‐CoV‐2 infection since the exposure and post symptoms onset.medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.23.20041707.
Liao X, 2020, A Case Report of Moderate COVID‐19 with an Extremely Long‐Term Viral Shedding Period in China
Fan BX, 2004, Relationship of IgG antibody level and its duration with prognosis in convalescent patients with severe acute respiratory syndrome, Chin J Clin Rehab, 8, 1702
Shi YL, 2010, Study on the changing regularity of special antibody and expression of stomach and enteric involvement on SARS‐coronavirus infection in the recovery period of severe acute respiratory syndrome, Zhonghua Liu Xing Bing Xue Za Zhi, 31, 795
Chinese National Health Commission, 2020, Chinese Clinical Guidance for COVID‐19 Pneumonia Diagnosis and Treatment
Ng KW, 2020, Pre‐existing and de novo humoral immunity to SARS‐CoV‐2 in humans, bioRxiv
KCDC. Findings from investigation and analysis of re‐positive cases. May 19 2020.https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030#. Accessed May 29 2020.
The National Institute for Biological Standards and Control (NIBSC). Coronavirus (COVID‐19)‐related research reagents.https://nibsc.org/science_and_research/idd/cfar/covid-19_reagents.aspx. 2020. Accessed August 17 2020.
HarringtonP CartyP FawsittC et al. Rapid health technology assessment of alternative diagnostic testing approaches for the detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2).https://www.hiqa.ie/sites/default/files/2020-05/Rapid_HTA_COVID-19_tests.pdf. 2020. Accessed August 1 2020.
CDC. Interim guidelines for COVID‐19 antibody testing in clinical and public health settings.https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html. 2020. Accessed: June 1 2020.